Converge Bio did not wake up one morning and decide to chase AI drug discovery because it sounded good on a pitch deck. This story starts in March 2024, in the collision zone between code, cells, and zero patience for how slow medicine still moves. Boston HQ, Tel Aviv R&D, and a founding team fluent in biology and machine learning in equal measure. About 18 months later, that conviction locked in $25M Series A capital, announced Jan 13, 2026, and nobody involved looked shocked.
Dov Gertz, CEO and Co-Founder, comes from the rare category of builders who publish, patent, and ship. A master’s in bioinformatics from Tel Aviv University, a licensed U.S. patent from discovering novel CRISPR systems, and peer-reviewed research alongside Nobel laureate Jennifer Doudna will do that. Oded Kalev, CTO and Co-Founder, brings the muscle memory of leading 20-person ML teams at Perception Point, applying LLMs to RNA analysis during COVID on a home GPU before it was polite conversation. Dr. Iddo Weiner, Chief Scientific Officer and Co-Founder, led 2 drug programs through positive Phase 2 readouts at BiomX, finished a PhD in record time, and published 10 papers while most people were still drafting outlines.
The platform treats biology like language and molecules like meaning. LLMs trained on DNA, RNA, protein sequences, and small molecules generate candidates, while predictive systems and physics-based docking keep imagination on a leash. Antibody design, protein yield optimization, target discovery, biomarker identification, and mRNA vaccine design, all without asking scientists to become software engineers. Think 4–7x manufacturing yield gains, single-digit nanomolar binding affinities, and experimental validation that shows up in the lab, not just the slide deck.
Investors noticed. Bessemer Venture Partners led the Series A, with Andrew Hedin taking a board seat. TLV Partners returned after leading the $5.5M seed, joined by Vintage Investment Partners, Saras Capital, and execs from Meta, OpenAI, and Wiz. Total funding now sits at $30M. Oversubscribed rounds tend to happen when the math works and the story survives real diligence.
The operating metrics back it up. 9 employees in Nov 2024 became 34 by Jan 2026, with a 40-person team where roughly 50% hold advanced degrees. 40+ programs delivered in the past year. 40+ partnerships. Active customers across the U.S., Canada, Europe, and Israel, including Teva, Compugen, and BiomX, with Asia next. Nebius infrastructure powers a full-transcriptome foundation model reasoning across 20,000+ genes per cell with speed and explainability intact.
Drug discovery has spent decades lighting capital on fire with educated guesses. Converge Bio is betting that experimentally validated generative systems, explainable outputs, and customer-owned data compress timelines without compressing trust. The industry calls this the largest financial opportunity in life sciences. Converge Bio seems more interested in proving it molecule by molecule, quietly converging computation and chemistry until the old timelines start to feel embarrassing.
